India Business News: BDR Pharma launches BDENZA (Enzalutamide), the world's first oral solution for prostate cancer management. BDENZA is priced at Rs 27,000 for 150mL, of
The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Masofaniten administered in combination with enzalutamide (Xtandi) was tolerable, pharmacokinetically active, and led to a decrease in prostate-specific antigen levels at the recommended phase 2 dose in patients with metastatic castration-resistant prostate cancer.